Skip to content

Press Release Details

Haemonetics 4th Quarter Fiscal Year 2022 Earnings Release Available on Investor Relations Website

May 10, 2022

Financial release accessible online

BOSTON, May 10, 2022 /PRNewswire/ -- Haemonetics Corporation (NYSE: HAE) announced that financial results for its fourth quarter fiscal 2022, which ended April 2, 2022, are available on its Investor Relations website.

The Company will host a conference call and webcast with investors and analysts to discuss and answer questions about the results at 8:00 a.m. EDT on May 10, 2022. The conference call and webcast can be accessed with the following information:

  • U.S. / Canada toll free (877) 848-8880; International (716) 335-9512
  • Conference ID required for access: 5347317
  • A live webcast of the call can be accessed on Haemonetics' Investor Relations website or via the following link:

In addition, the Company has posted to its Investor Relations website the earnings release and analytical tables and supplemental information that will be referenced on its conference call and webcast, direct links to which are available below.  

Direct link to 4Q FY22 Earnings Release:

Direct link to 4Q FY22 Analytical Tables and Supplemental Information:

A replay of the conference call and webcast will be available for one year beginning on May 10, 2022, at 11:00 a.m. EDT using the conference call webcast link provided in this press release.

About Haemonetics
Haemonetics (NYSE: HAE) is a global healthcare company dedicated to providing a suite of innovative medical products and solutions for customers, to help them improve patient care and reduce the cost of healthcare. Our technology addresses important medical markets: blood and plasma component collection, the surgical suite and hospital transfusion services. To learn more about Haemonetics, visit

Investor Contacts:

Olga Guyette, Sr. Director-Investor Relations & Treasury

David Trenk, Manager-Investor Relations

(781) 356-9763

(203) 733-4987



Media Contact:

Josh Gitelson, Director-Global Communications

(781) 356-9776



Cision View original content to download multimedia:

SOURCE Haemonetics Corporation